
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
β-2-Microglobulin CRISPR Activation Plasmid (m) | sc-419281-ACT | 20 µg | $397.00 | |||
β-2-Microglobulin CRISPR Activation Plasmid (m2) | sc-419281-ACT-2 | 20 µg | $397.00 |
B2m encodes β-2-microglobulin, a conserved component of MHC class I complexes required for proper folding, surface stability, and peptide presentation to CD8+ T cells. In mouse cells, β-2-microglobulin supports antigen processing and presentation pathways that coordinate immune surveillance, interferon-responsive gene programs, and tolerance mechanisms. Altered B2m expression or function is widely used as a model for changes in MHC I display that influence immune recognition, inflammation, and host–pathogen interactions. As a housekeeping immune component, it is also relevant for studies of transplant biology, tumor–immune interactions, and cell engineering workflows where MHC I modulation affects immune compatibility.
β-2-Microglobulin CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous B2m expression without altering the underlying DNA sequence.
β-2-Microglobulin CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the B2m locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the B2m transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous β-2-Microglobulin expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native B2m locus and enabling the study of β-2-Microglobulin-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of β-2-Microglobulin pathway restoration in tumor cells with silenced or reduced B2m expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.